Global Ambition Begins

India's largest pharmaceutical company, Sun Pharma, announced its biggest-ever acquisition. This strategic move aims to expand overseas market share and gain entry into U.S. and European regulatory regimes. The deal also reflects an intention to strengthen research and development (R&D) capabilities.

Infrastructure, Capital, and Policy Gaps

However, the Indian pharmaceutical sector still lacks adequate production facilities and supply-chain infrastructure, and faces constraints in raising large-scale capital. Insufficient policy support makes building an innovative new‑drug pipeline challenging. These structural limitations could hinder the achievement of global competitiveness.

Competitive Landscape with China

China has already emerged as a research‑focused pharmaceutical powerhouse through massive investment and government‑driven biotech clusters. India seeks differentiation by leveraging its population size and cost competitiveness, but currently lags behind in infrastructure and capital scale. Consequently, Indian companies will need sustained investment and policy reforms to create differentiated portfolios for global markets.

Future Scenarios and Impact

Sun Pharma's acquisition could serve as a signal of Indian pharma's push into global markets. If integration succeeds and R&D capabilities are elevated, the share of overseas sales could rise substantially. Conversely, failure to address infrastructure and policy issues could result in performance falling short of expectations.